MedTrace Logo

Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness

NCT02972411 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-11-23

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of the voluntary ventilatory response as prophylaxis for acute mountain sickness, measured by the Lake Louise Self-Report Score, comparing to a group using acetazolamide.

Conditions

  • Altitude Sickness

Interventions

BEHAVIORAL

Voluntary ventilatory response

Training of the subjects for voluntary increase in the respiratory minute ventilation

DRUG

Acetazolamide

Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude

Sponsors & Collaborators

  • Hospital del Trabajador de Santiago

    lead OTHER

Principal Investigators

  • Sebastián Drago, MD · Hospital del Trabajador Santiago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02972411 on ClinicalTrials.gov